GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (OSTO:ONCOZ) » Definitions » Equity-to-Asset

OncoZenge AB (OSTO:ONCOZ) Equity-to-Asset : 0.94 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is OncoZenge AB Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. OncoZenge AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr16.27 Mil. OncoZenge AB's Total Assets for the quarter that ended in Mar. 2024 was kr17.23 Mil.

The historical rank and industry rank for OncoZenge AB's Equity-to-Asset or its related term are showing as below:

OSTO:ONCOZ' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.77   Med: 0.93   Max: 1.02
Current: 0.94

During the past 4 years, the highest Equity to Asset Ratio of OncoZenge AB was 1.02. The lowest was 0.77. And the median was 0.93.

OSTO:ONCOZ's Equity-to-Asset is ranked better than
93.27% of 1560 companies
in the Biotechnology industry
Industry Median: 0.67 vs OSTO:ONCOZ: 0.94

OncoZenge AB Equity-to-Asset Historical Data

The historical data trend for OncoZenge AB's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoZenge AB Equity-to-Asset Chart

OncoZenge AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
0.77 0.94 0.92 0.92

OncoZenge AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 0.91 0.89 0.92 0.94

Competitive Comparison of OncoZenge AB's Equity-to-Asset

For the Biotechnology subindustry, OncoZenge AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoZenge AB's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoZenge AB's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where OncoZenge AB's Equity-to-Asset falls into.



OncoZenge AB Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

OncoZenge AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=18.641/20.34
=

OncoZenge AB's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=16.266/17.233
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoZenge AB  (OSTO:ONCOZ) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


OncoZenge AB Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of OncoZenge AB's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoZenge AB (OSTO:ONCOZ) Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 34, Bromma, SWE, 167 51
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

OncoZenge AB (OSTO:ONCOZ) Headlines

No Headlines